DEST — Destiny Pharma Income Statement
0.000.00%
Last trade - 00:00- £3.83m
- -£2.55m
Annual income statement for Destiny Pharma, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 5.58 | 6.55 | 6.29 | 7.78 | 6.74 |
| Operating Profit | -5.58 | -6.55 | -6.29 | -7.78 | -6.74 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -5.52 | -6.48 | -6.27 | -7.71 | -6.45 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -4.71 | -5.41 | -5.34 | -6.5 | -5.66 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -4.71 | -5.41 | -5.34 | -6.5 | -5.66 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.71 | -5.41 | -5.34 | -6.5 | -5.66 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.107 | -0.12 | -0.089 | -0.093 | -0.062 |